Spring til hovednavigation Spring til søgning Spring til hovedindhold

Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

Michael Weichenthal*, Eva Ellebaek

*Corresponding author af dette arbejde
OriginalsprogEngelsk
Artikelnummer101149
Tidsskrift EJC Skin Cancer
Vol/bind4
Antal sider1
DOI
StatusUdgivet - 22 jun. 2026

Citationsformater